No Differences in Gastrointestinal Bleeding Risk among Clopidogrel-, Ticagrelor-, or Prasugrel-Based Dual Antiplatelet Therapy

Podobne zapisy

• No Differences in Gastrointestinal Bleeding Risk among Clopidogrel-, Ticagrelor-, or Prasugrel-Based Dual Antiplatelet Therapy
  od: Viviana Laredo, i wsp.
  Wydane: (2020-05-01)
• Fewer gastrointestinal bleeds with ticagrelor and prasugrel compared with clopidogrel in patients with acute coronary syndrome following percutaneous coronary intervention
  od: Abraham, Neena S., i wsp.
  Wydane: (2020)
• Cost-effectiveness of clopidogrel, prasugrel and ticagrelor for dual antiplatelet therapy after acute coronary syndrome: a decision-analytic model
  od: Abdel-Qadir, Husam, i wsp.
  Wydane: (2015)
• Alternatives to clopidogrel for acute coronary syndromes: Prasugrel or ticagrelor?
  od: Biondi-Zoccai, Giuseppe, i wsp.
  Wydane: (2010)
• Bleeding complications after dual antiplatelet therapy with ticagrelor versus dual antiplatelet therapy with clopidogrel—a propensity-matched comparative study of two antiplatelet regimes in off-pump coronary artery bypass grafting
  od: Varma, Praveen Kerala, i wsp.
  Wydane: (2020)